“Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 ”. SKIN The Journal of Cutaneous Medicine 6, no. 2 (March 4, 2022): s2. Accessed September 25, 2025. https://skin.dermsquared.com/skin/article/view/1517.